Clinical trials: Sunitinib
Kidney Cancer
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00459875
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment
The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments.
- Trial name
- NCT01370980
- Where
- Switzerland
- Volunteers
- 43 people
- Sponsor
- Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Kidney Cancer
Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of kidney cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00459979
- Testing
- sunitinib malate, conventional surgery
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
This phase I trial studies the side effects and the best dose of sunitinib malate when given together with bevacizumab in treating patients with kidney cancer or advanced solid malignancies.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
- Trial name
- NCT01243359
- Testing
- sunitinib malate, bevacizumab, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Clinical Trial of Sutent to Treat Metastatic Melanoma
The purpose of this study is to investigate whether an investigational drug called sunitinib malate is safe and effective in treating metastatic melanoma in patients with KIT mutations.
- Trial name
- NCT00631618
- Testing
- Sutent (sunitinib)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- California Pacific Medical Center Research Institute
Non-Clear Cell Renal Cell Carcinoma
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received…
- Trial name
- STELLAR-304 (NCT05678673)
- Testing
- XL092, Nivolumab, Sunitinib Malate
- Where
- 163 sites in United States, Argentina and 23 more
- Volunteers
- 317 people
- Sponsor
- Exelixis
Metastatic Renal Cell Carcinoma
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively.
- Trial name
- NCT05816642
- Testing
- sunitinib or pazopanib, PD-1 inhibitor combined with axitinib
- Where
- China
- Volunteers
- 500 people
- Sponsor
- RenJi Hospital
Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
This randomized phase II trial studies how well trebananib with or without bevacizumab, pazopanib hydrochloride, sorafenib tosylate, or sunitinib malate works in treating patients with kidney cancer that has spread to other…
- Conditions
- Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT01664182
- Testing
- Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Neoplasms
Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.
- Trial name
- NCT00054886
- Testing
- SU-011,248
- Where
- 15 sites in United States
- Volunteers
- 63 people
- Sponsor
- Pfizer
Pancreatic Cancer
Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the tyrosine kinases needed for angiogenesis and cell growth.
- Trial name
- PACT-12 (NCT00967603)
- Testing
- sunitinib
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- IRCCS San Raffaele
Colorectal Neoplasms
Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer
To assess the safety and tolerability of sunitinib when administered in combination with modified FOLFOX6 in Japanese patients with metastatic colorectal cancer in the first-line treatment setting.
- Trial name
- NCT00631410
- Testing
- sunitinib + mFOLFOX6
- Where
- 3 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
Information on the prevalence of advanced/metastatic renal cell carcinoma and its symptom burden is limited in commercially insured patients (age >= 18 years and < 65 years).
- Trial name
- NCT01381614
- Testing
- Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Complete Remission in Renal Cell Carcinoma
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
This prospective study will investigate the characteristics of mRCC patients at time of CR in comparison with mRCC patients non on CR treated with Sunitinib, in order to provide some answers/ refection leads to the following…
- Trial name
- APERCU (NCT01934452)
- Testing
- sunitinib
- Where
- 14 sites in France
- Volunteers
- 77 people
- Sponsor
- Pfizer
Breast Cancer
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00482755
- Testing
- sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- NCIC Clinical Trials Group
Cancer
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
This study will aims to determine the maximum tolerated dose of CGC-11047 when used in individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or cisplatin or 5-flurouracil or sunitinib in one of 7…
- Trial name
- NCT00705874
- Testing
- CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 172 people
- Sponsor
- Progen Pharmaceuticals
Metastatic Renal Cell Carcinoma
Clinical Trial to Assess the Importance of Nephrectomy
The study compare the standard treatment with nephrectomy + sunitinib to treatment with sunitinib alone without nephrectomy. This study will be the first trial on this competitive context
- Trial name
- CARMENA (NCT00930033)
- Testing
- Nephrectomy, Sunitinib alone
- Where
- France
- Volunteers
- 452 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type B3 Thymoma, Thymic Carcinoma
Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
Study to investigate response to sunitinib in patients with thymic epithelial tumours who had progressive disease after at least one previous regimen of platinum-based chemotherapy.
- Trial name
- Style (NCT03449173)
- Testing
- Sunitinib
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Kidney Cancer
Sunitinib Malate in Treating Patients With Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00943839
- Testing
- sunitinib malate, laboratory biomarker analysis, pharmacological study
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Antoine Lacassagne
Glioblastoma
Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients
Sunitinib seems to be a promising treatment for the objective of this proposal: to evaluate the clinical activity of Sunitinib as first line therapy in patients who have measurable disease and to evaluate the safety of Sunitinib…
- Trial name
- NCT01100177
- Testing
- Sunitinib, Radiation
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Grupo Español de Investigación en Neurooncología
Healthy
The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients
In this prospective pharmacokinetic we investigate the following topics: The influence of grapefruit juice and orange juice on the steady-state pharmacokinetics of sunitinib in cancer patients The influence of sunitinib on the…
- Trial name
- NCT01743300
- Testing
- Sunitinib, Midazolam, Orange juice
- Volunteers
- 15 people
- Sponsor
- Leiden University Medical Center